Shaun has global responsibility for Strategic Partnering & Business Development, dedicated to broadening AstraZeneca’s access to scientific innovation outside its own labs. His background includes ICI, Zeneca, and AstraZeneca in Corporate, Pharmaceuticals & US Legal departments, HR & Business Development. Major projects include the AstraZeneca merger, creation of Avecia & Syngenta, acquisition of Cambridge Antibody Technology, MedImmune & Amylin, and the spin out of Albireo.
In a 40+ year career, during which he has served with 4 of the top 10 pharma companies, David was named as co-inventor on the patent for Viagra and played a pivotal role in the discovery of Relpax, a treatment for Migraine. More recently, he has co-founded companies including Crescendo Biologics and Healx. An active angel investor, David chairs the board of Healx, ProFactor Pharma and Babraham Institute Enterprises Ltd.
Mark has 25+ years’ experience in the discovery of novel treatments for diseases of the nervous system. Following an early career at Pfizer, he founded Cambridge Drug Discovery and served as CEO, growing the company to exit to BioFocus for £28m. Over the past 15 years, Mark has helped to raise over £150m for various early-stage biotechnology companies and has served on the boards of 16 private and public companies.
Denise has over 25 years experience in the biopharmaceutical industry, in R&D management and as a VC. In 1999 she joined Nomura and became MD after heading the life science investment team investing globally in biotech companies. She led the Phase4 Partners MBO from Nomura in 2010. Denise has served on many US and European private and public boards, including Idenix (until acquired by Merck for $3.85bn).
Fiona was Founder & CSO of Heptares,a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Heptares was acquired by Japanese biopharmaceutical giant Sosei Group in a $400m deal in 2015.
Melanie was Founding CEO and now NED of NightstaRx, a Syncona backed private biopharmaceutical company specialised in bringing sight improving treatments to patients with retinal dystrophies. Melanie is currently CSO of BTG plc, a fast growing Interventional Medicine company on the international stage with its HQ in London.
Vishal is one of Europe’s leading digital healthcare investors. A Partner at Draper Esprit, one of the largest and most active VC firms in Europe, Vishal is a qualified physician and chairman of the Digital Health Forum. Over the last decade he has championed deals across areas including diagnostics, devices & biotech.
An experienced entrepreneur, physician and business leader, Richard works to catalyse early innovations and discover opportunities for collaboration and investment across Johnson & Johnson’s global healthcare businesses. Prior to joining J&J Innovation, Richard was CEO at XO1 before the company was acquired in a J&J Innovation facilitated deal in 2015.
Peter is Co-founder of LayerWise, an innovative & award winning spin-out from the University of Leuven, active in metal Additive Manufacturing for industrial, dental and medical applications. Peter grew the company as MD to acquisition by 3D Systems Corporation in 2014.
Cathy is Mentor to the Ignite Summer Business School Programme at the Centre for Entrepreneurial Learning (University of Cambridge); Senior Associate for the Masters in Bioscience Enterprise (University of Cambridge) & Visiting Professor at Kings College, London. Previously, Cathy chaired the UK National Stem Cell Network Advisory committee.